Alimentary Pharmacology & Therapeutics

Article	Citations
Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19	181
Editorial: low population mortality from COVID‐19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity	172
2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases	142
Review article: COVID‐19 and liver disease—what we know on 1st May 2020	130
Letter: Covid‐19, and vitamin D	112
Systematic review with meta‐analysis: SARS‐CoV‐2 stool testing and the potential for faecal‐oral transmission	104
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis	102
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data	102
Long‐term safety of vedolizumab for inflammatory bowel disease	92
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment	89
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease	89
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world	88
Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient	83
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor	81
Systematic review: the global incidence of faecal microbiota transplantation‐related adverse events from 2000 to 2020	80
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging	79
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease	78
Review article: FODMAPS, prebiotics and gut health‐the FODMAP hypothesis revisited	75
Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry	71
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment	69
Liver involvement is not associated with mortality: results from a large cohort of SARS‐CoV‐2‐positive patients	67
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome	66
Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma	65
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices	62
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry	59

Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease	57
A disease‐specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis	54
Systematic review and network meta‐analysis: efficacy of drugs for functional dyspepsia	52
Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000‐2018	51
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH	51
Randomised clinical trial: standard of care versus early‐transjugular intrahepatic porto‐systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding	51
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy	50
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study	50
Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis	49
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients	49
Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests	49
Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers	49
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis	49
Systematic review with meta‐analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients	48
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents	48
Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study	47
Improvement in histological endpoints of MAFLD following a 12‐week aerobic exercise intervention	47
Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma	46
Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma	45
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study	45
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations	45
Systematic review with meta‐analysis: COVID‐19 outcomes in patients receiving anti‐TNF treatments	44
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease	44
Review article: prognostic significance of body composition abnormalities in patients with cirrhosis	43
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases	43
Exposure sources, amounts and time course of gluten ingestion and excretion in patients with coeliac disease on a gluten‐free diet	43
Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry	42
Outcomes after hepatic encephalopathy in population‐based cohorts of patients with cirrhosis	41
Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab	41
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase	40
Novel impedance‐pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro‐oesophageal reflux disease according to Lyon Consensus	39
Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti‐TNF biological agents: real‐world registry data from the Persistence Austral	39
Review article: emerging drug therapies in inflammatory bowel disease	38
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality	38
Review article: impact of cigarette smoking on intestinal inflammation—direct and indirect mechanisms	38
Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study	37
Systematic review with meta‐analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure	37
Randomised clinical trial: palliative long‐term abdominal drains vs large‐volume paracentesis in refractory ascites due to cirrhosis	37
Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases	37
Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease	37
Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom	37
Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders	36
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk	36
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis	36
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study	36
Umbrella review of 42 systematic reviews with meta‐analyses: the safety of proton pump inhibitors	36
East Asia expert opinion on treatment initiation for chronic hepatitis B	36
Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease	36
The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent	35
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure	35

Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease	35
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	35
Systematic review with meta‐analysis: efficacy of balloon‐assisted enteroscopy for dilation of small bowel Crohn's disease strictures	34
Letter: Covid‐19, and vitamin D. Authors' reply	34
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute‐on‐chronic liver failure	33
Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease	32
Patients with severe acute‐on‐chronic liver failure are disadvantaged by model for end‐stage liver disease‐based organ allocation policy	32
Systematic review: gastrointestinal infection and incident inflammatory bowel disease	32
Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease	32
Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease	32
Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome	31
Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B	31
Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics	31
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy	31
A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment	31
Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis	31
Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders	31
Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea	30
Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease	30
Systematic review with meta‐analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations	30
Systematic review with meta‐analysis: the efficacy and safety of direct‐acting antivirals in children and adolescents with chronic hepatitis C virus infection	30
Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis	30
Risk of severe COVID‐19 in patients treated with IBD medications: a French nationwide study	29
Impact of Rome IV irritable bowel syndrome on work and activities of daily living	29
Inflammatory bowel disease and pancreatic cancer: a Scandinavian register‐based cohort study 1969‐2017	29
Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis	29
The association between markers of liver injury and clinical outcomes in patients with COVID‐19 in Wuhan	29
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study	29
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease	28
Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden	28
Meta‐analysis: global prevalence, trend and forecasting of non‐alcoholic fatty liver disease in children and adolescents, 2000–2021	28
Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer	28
Systematic review with meta‐analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria	28
Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy	28
Systematic review with meta‐analysis: effectiveness of anti‐inflammatory therapy in immune checkpoint inhibitor‐induced enterocolitis	28
Increasing comorbidities in a South Korea insured population‐based cohort of patients with chronic hepatitis B	28
Prevalence of coeliac disease in Northwest China: heterogeneity across Northern Silk road ethnic populations	28
Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease	28
Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing	27
Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease	27
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study	27
Efficacy and safety of tenofovir alafenamide fumarate for preventing mother‐to‐child transmission of hepatitis B virus: a national cohort study	27
Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure	27
Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT‐based surveillance	27
Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma	27
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study	27
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplant	26
Systematic review with meta‐analysis: artificial intelligence in the diagnosis of oesophageal diseases	26
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort	26
Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis	26
Circulating lipidomic alterations in obese and non‐obese subjects with non‐alcoholic fatty liver disease	26
Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease	26
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver	26
Review article: bugs, inflammation and mood—a microbiota‐based approach to psychiatric symptoms in inflammatory bowel diseases	26
Review article: obesity and colorectal cancer	25
Review Article: vaccination for patients with inflammatory bowel disease during the COVID‐19 pandemic	25
Review article: time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment	25
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database	25
One‐quarter of chronic hepatitis D patients reach HDV‐RNA decline or undetectability during the natural course of the disease	25
Applying Lyon Consensus criteria in the work‐up of patients with proton pump inhibitory‐refractory heartburn	25
A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014	25
Systematic review and meta‐analysis: the incidence and prevalence of paediatric coeliac disease across Europe	25
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study	25
In utero exposure to thiopurines/anti‐TNF agents and long‐term health outcomes during childhood and adolescence in Denmark	24
Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease	24
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study	24
Comorbidity before and after a diagnosis of inflammatory bowel disease	24
Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease	24
Paediatric infections in the first 3 years of life after maternal anti‐TNF treatment during pregnancy	24
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome	24
Review article: pathophysiology and management of primary biliary cholangitis	24
Editorial: low population mortality from COVID‐19 in countries south of latitude 35 degrees North—supports vitamin D as a factor determining severity. Authors' reply	24
Systematic review: medical therapy for fibrostenosing Crohn’s disease	24
Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study	24
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease	23
Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease	23
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease	23
Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States	23
Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis	23
Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data	23

Oesophageal hypervigilance and visceral anxiety relate to reflux symptom severity and psychological distress but not to acid reflux parameters	22
Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication	22
Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease	22
Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study	22
Systematic review: management of localised low‐grade upper gastrointestinal neuroendocrine tumours	22
Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease	22
Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg‐positive chronic hepatitis B treated with nucleos(t)ide analogues	22
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease	22
Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease	22
Carvedilol is associated with improved survival in patients with cirrhosis: a long‐term follow‐up study	21
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti‐TNF: a French nationwide study 2010–2018	21
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn’s disease	21
Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct‐acting anti‐virals	21
Systematic review with meta‐analysis: IBD‐associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present)	21
Systematic review with meta‐analysis: one‐year outcomes of gastric peroral endoscopic myotomy for refractory gastroparesis	21
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	21
Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor	21
Digital pathology: accurate technique for quantitative assessment of histological features in metabolic‐associated fatty liver disease	21
Multiomic features associated with mucosal healing and inflammation in paediatric Crohn’s disease	21
Large‐scale genome‐wide association study identifies HLA class II variants associated with chronic HBV infection: a study from Taiwan Biobank	21
Systematic review with meta‐analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer	20
Antioxidants, minerals and vitamins in relation to Crohn's disease and ulcerative colitis: A Mendelian randomization study	20
Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation	20
Review article: the future of microbiome‐based therapeutics	20
Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis ‐ a unique therapeutic target in inflammatory bowel disease	20
Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010‐2018	20
Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication	20
Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies	20
Sugar‐sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants	20
Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin	19
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota	19
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence	19
Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination	19
Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study	19
Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis	19
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates	19
Longitudinal follow‐up study: effect of psychological co‐morbidity on the prognosis of inflammatory bowel disease	19
Systematic review: development of a consensus code set to identify cirrhosis in electronic health records	19
Systematic review with meta‐analysis: limited benefits from early colonoscopy in acute lower gastrointestinal bleeding	19
Vagotomy and subsequent risk of inflammatory bowel disease: a nationwide register‐based matched cohort study	19
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study	19
Fatigue in inflammatory bowel disease and its impact on daily activities	19
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases	19
Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease	19
The impact of genetic risk on liver fibrosis in non‐alcoholic fatty liver disease as assessed by magnetic resonance elastography	18
Long‐term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids	18
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease	18
Review article: current and emerging therapies for the management of cirrhosis and its complications	18
Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease	18
Colectomy rates for ulcerative colitis in England 2003‐2016	18
Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population‐based studies	18
Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population‐based study	18
Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD	18
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)	18
Review article: liver disease in adults with variants in the cholestasis‐related genes ABCB11, ABCB4 and ATP8B1	18
Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma	18
PRO‐C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol‐related liver disease	18
Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases	18
Factors associated with lower disease‐specific and generic health‐related quality of life in Rome IV irritable bowel syndrome	18
Clinical classification and long‐term outcomes of seronegative coeliac disease: a 20‐year multicentre follow‐up study	18
Systematic review with meta‐analysis: abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis	18
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials	18
One‐year outcomes with ustekinumab therapy in infliximab‐refractory paediatric ulcerative colitis: a multicentre prospective study	18
Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis	18
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis	17
Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study	17
Longitudinal follow‐up of a novel classification system for irritable bowel syndrome: natural history and prognostic value	17
The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis	17
The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care	17
Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression	17
Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta‐analyses	17
Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels	17
The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease—results from the Stress, Anxiety and Depression with Disease Activity (SADD) St	17
Adjustment of azathioprine dose should be based on a lower 6‐TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers	17
Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease	17
Transcutaneous vagus nerve stimulation prevents the development of, and reverses, established oesophageal pain hypersensitivity	17
NAFLD‐related gene polymorphisms and all‐cause and cause‐specific mortality in an Asian population: the Shanghai Changfeng Study	17
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero	17
A single nucleotide polymorphism genetic risk score to aid diagnosis of coeliac disease: a pilot study in clinical care	17
Systematic review—pancreatic involvement in inflammatory bowel disease	17
Collagen proportionate area predicts clinical outcomes in patients with alcohol‐related liver disease	17
Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis	17
Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease	17
Systematic review with meta‐analysis: the accuracy of serological tests to support the diagnosis of coeliac disease	16
Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease	16
Durable virological response and functional cure of chronic hepatitis D after long‐term peginterferon therapy	16
Profiles of serum soluble programmed death‐1 and programmed death‐ligand 1 levels in chronic hepatitis B virus‐infected patients with different disease phases and after anti‐viral treatment	16
Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease	16
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis	16
Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management	16
Letter: does vitamin D have a potential role against COVID‐19?	16
Systematic review with meta‐analysis: efficacy and safety of treatments for opioid‐induced constipation	16
Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy	16
A comparative analysis of tioguanine versus low‐dose thiopurines combined with allopurinol in inflammatory bowel disease patients	16
Randomised clinical trial: a 12‐strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections	16